Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients

Lung Cancer

Volumn 63, Issue 1, 2009, Pages 121-127

  Soo, Ross A ^a   Wang, Ling Zhi ^a   Ng, Swee Siang ^b   Chong, Pei Yi ^b   Yong, Wei Peng ^a   Lee, Soo Chin ^a   Liu, Jian Jun ^c   Choo, Tai Bee ^b   Tham, Lai San ^a   Lee, How Sung ^c   Goh, Boon Cher ^a,b   Soong, Richie ^b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

Ethnicity; Gemcitabine; Gene variants; Non small cell lung cancer; Polymorphism

Indexed keywords

CARBOPLATIN; DNA; GEMCITABINE;

ADULT; AGED; ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER GROWTH; CAUCASIAN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; PYROSEQUENCING; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CYTIDINE DEAMINASE; DEOXYCYTIDINE; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHARMACOGENETICS; RETROSPECTIVE STUDIES; SINGAPORE; TREATMENT OUTCOME;

EID: 57649112390     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.04.010     Document Type: Article

References (32)

1. Toschi L., Finocchiaro G., Bartolini S., Gioia V., and Cappuzzo F. Role of gemcitabine in cancer therapy. Future Oncol 1 (2005) 7-17
2. Evans W.E., and McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348 (2003) 538-549
3. Maring J.G., Groen H.J., Wachters F.M., Uges D.R., and de Vries E.G. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 5 (2005) 226-243
4. Ulrich C.M., Robien K., and McLeod H.L. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 3 (2003) 912-920
5. Lee S.C., Ng S.S., Oldenburg J., Chong P.Y., Rost S., Guo J.Y., et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 79 (2006) 197-205
6. Soong R., and Diasio R.B. Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics 6 (2005) 835-847
7. Kong W., Engel K., and Wang J. Mammalian nucleoside transporters. Curr Drug Metab 5 (2004) 63-84
8. Mackey J.R., Yao S.Y., Smith K.M., Karpinski E., Baldwin S.A., Cass C.E., et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 91 (1999) 1876-1881
9. Heinemann V., Hertel L.W., Grindey G.B., and Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-d-arabinofuranosylcytosine. Cancer Res 48 (1988) 4024-4031
10. Plunkett W., Huang P., and Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 6 Suppl. 6 (1995) 7-13
11. Heinemann V., Xu Y.Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38 (1990) 567-572
12. Heinemann V., Xu Y.Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 52 (1992) 533-539
13. Bergman A.M., Pinedo H.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., and Peters G.J. Cross-resistance of the gemcitabine resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Adv Exp Med Biol 431 (1998) 587-590
14. Fukunaga A.K., Marsh S., Murry D.J., Hurley T.D., and McLeod H.L. Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 4 (2004) 307-314
15. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
16. Bepler G., Zheng Z., Gautam A., Sharma S., Cantor A., Sharma A., et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 47 (2005) 183-192
17. Gray J.H., Mangravite L.M., Owen R.P., Urban T.J., Chan W., Carlson E.J., et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol 65 (2004) 512-519
18. Kawakami K., and Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63 (2003) 6004-6007
19. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
20. de las Penas R., Sanchez-Ronco M., Alberola V., Taron M., Camps C., Garcia-Carbonero R., et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17 (2006) 668-675
21. Quintela-Fandino M., Hitt R., Medina P.P., Gamarra S., Manso L., Cortes-Funes H., et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24 (2006) 4333-4339
22. Sakano S., Wada T., Matsumoto H., Sugiyama S., Inoue R., Eguchi S., et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer 95 (2006) 561-570
23. Stoehlmacher J., Park D.J., Zhang W., Yang D., Groshen S., Zahedy S., et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91 (2004) 344-354
24. Zhang W., Gordon M., Press O.A., Rhodes K., Vallbohmer D., Yang D.Y., et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genom 16 (2006) 475-483
25. Owen R.P., Gray J.H., Taylor T.R., Carlson E.J., Huang C.C., Kawamoto M., et al. Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. Pharmacogenet Genomics 15 (2005) 83-90
26. Sugiyama E., Kaniwa N., Kim S.R., Kikura-Hanajiri R., Hasegawa R., Maekawa K., et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25 (2007) 32-42
27. Yonemori K., Ueno H., Okusaka T., Yamamoto N., Ikeda M., Saijo N., et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11 (2005) 2620-2624
28. Wood A.J., and Zhou H.H. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 20 (1991) 350-373
29. Poolsup N., Li Wan Po A., and Knight T.L. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 25 (2000) 197-220
30. Roh H.K., Dahl M.L., Tybring G., Yamada H., Cha Y.N., and Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 6 (1996) 547-551
31. Rudd R.M., Gower N.H., Spiro S.G., Eisen T.G., Harper P.G., Littler J.A., et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23 (2005) 142-153
32. Sederholm C., Hillerdal G., Lamberg K., Kolbeck K., Dufmats M., Westberg R., et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 23 (2005) 8380-8388